Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Biol Chem ; 286(1): 594-606, 2011 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-21047781

RESUMO

The neuronal α7 nicotinic receptor subunit gene (CHRNA7) is partially duplicated in the human genome forming a hybrid gene (CHRFAM7A) with the novel FAM7A gene. The hybrid gene transcript, dupα7, has been identified in brain, immune cells, and the HL-60 cell line, although its translation and function are still unknown. In this study, dupα7 cDNA has been cloned and expressed in GH4C1 cells and Xenopus oocytes to study the pattern and functional role of the expressed protein. Our results reveal that dupα7 transcript was natively translated in HL-60 cells and heterologously expressed in GH4C1 cells and oocytes. Injection of dupα7 mRNA into oocytes failed to generate functional receptors, but when co-injected with α7 mRNA at α7/dupα7 ratios of 5:1, 2:1, 1:1, 1:5, and 1:10, it reduced the nicotine-elicited α7 current generated in control oocytes (α7 alone) by 26, 53, 75, 93, and 94%, respectively. This effect is mainly due to a reduction in the number of functional α7 receptors reaching the oocyte membrane, as deduced from α-bungarotoxin binding and fluorescent confocal assays. Two additional findings open the possibility that the dominant negative effect of dupα7 on α7 receptor activity observed in vitro could be extrapolated to in vivo situations. (i) Compared with α7 mRNA, basal dupα7 mRNA levels are substantial in human cerebral cortex and higher in macrophages. (ii) dupα7 mRNA levels in macrophages are down-regulated by IL-1ß, LPS, and nicotine. Thus, dupα7 could modulate α7 receptor-mediated synaptic transmission and cholinergic anti-inflammatory response.


Assuntos
Anti-Inflamatórios/farmacologia , Colina/metabolismo , Duplicação Gênica , Receptores Nicotínicos/genética , Acetilcolina/farmacologia , Regulação Alostérica/efeitos dos fármacos , Animais , Sítios de Ligação , Bungarotoxinas/metabolismo , Membrana Celular/efeitos dos fármacos , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Condutividade Elétrica , Células HL-60 , Humanos , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Oócitos/citologia , Oócitos/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Receptores Nicotínicos/metabolismo , Receptor Nicotínico de Acetilcolina alfa7
2.
Gene ; 380(1): 54-61, 2006 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-16876337

RESUMO

A small expansion of a CAG repeat domain in exon 47 of the human CACNA1A gene, which codes for the pore-forming alpha1A subunit of P/Q-type Ca2+ channels, causes spinocerebellar ataxia type-6. Only the human alpha1A protein has been demonstrated to contain the poly(Q) tract, although this locus has also recently been detected in ape genomes. To our knowledge, no further information has been published on other mammal species. Here, we have cloned the full-length alpha1A subunit in a non-primate species, the cow. The results have made it possible to explore the exon organization of the bovine CACNA1A gene as well as the splice alpha1A isoforms expressed by bovine chromaffin cells. We found a splice variant of the protein that, as in humans, also contains a polymorphic poly(Q) tract. Based on this result and using data from different Genome Databases, we performed an interspecies comparison of exon 47 and discovered that the poly(Q) tract is present in all the species studied, with the exception of primitive fish and rodents. Our results provide insight into the evolution of the CAG repeat tract at the C-terminus coding region of the CACNA1A gene.


Assuntos
Canais de Cálcio Tipo P/genética , Canais de Cálcio Tipo Q/genética , Ataxias Espinocerebelares/genética , Processamento Alternativo , Sequência de Aminoácidos , Animais , Sequência de Bases , Canais de Cálcio/genética , Bovinos , Células Cultivadas , Células Cromafins/metabolismo , Clonagem Molecular , Primers do DNA/genética , DNA Complementar/genética , Evolução Molecular , Éxons , Humanos , Íntrons , Dados de Sequência Molecular , Isoformas de Proteínas/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Homologia de Sequência de Aminoácidos , Homologia de Sequência do Ácido Nucleico , Especificidade da Espécie , Repetições de Trinucleotídeos
3.
PLoS One ; 11(6): e0157411, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27299810

RESUMO

PURPOSE: To test the efficacy of systemic gene delivery of a mutant form of erythropoietin (EPO-R76E) that has attenuated erythropoietic activity, in a mouse model of autosomal dominant retinitis pigmentosa. METHODS: Ten-day old mice carrying one copy of human rhodopsin with the P23H mutation and both copies of wild-type mouse rhodopsin (hP23H RHO+/-,mRHO+/+) were injected into the quadriceps with recombinant adeno-associated virus (rAAV) carrying either enhanced green fluorescent protein (eGFP) or EpoR76E. Visual function (electroretinogram) and retina structure (optical coherence tomography, histology, and immunohistochemistry) were assessed at 7 and 12 months of age. RESULTS: The outer nuclear layer thickness decreased over time at a slower rate in rAAV.EpoR76E treated as compared to the rAAV.eGFP injected mice. There was a statistically significant preservation of the electroretinogram at 7, but not 12 months of age. CONCLUSIONS: Systemic EPO-R76E slows death of the photoreceptors and vision loss in hP23H RHO+/-,mRHO+/+ mice. Treatment with EPO-R76E may widen the therapeutic window for retinal degeneration patients by increasing the number of viable cells. Future studies might investigate if co-treatment with EPO-R76E and gene replacement therapy is more effective than gene replacement therapy alone.


Assuntos
Eritropoetina/genética , Técnicas de Transferência de Genes , Terapia Genética , Células Fotorreceptoras Retinianas Cones/patologia , Retinose Pigmentar/patologia , Retinose Pigmentar/terapia , Animais , Morte Celular , Dependovirus/genética , Modelos Animais de Doenças , Eritropoetina/farmacocinética , Eritropoetina/uso terapêutico , Humanos , Camundongos , Opsinas/análise , Mutação Puntual , Retinose Pigmentar/genética , Retinose Pigmentar/fisiopatologia , Visão Ocular
4.
Eur J Neurosci ; 22(9): 2187-98, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16262657

RESUMO

Although the specific interaction between synaptic protein SNAP-25 and the alpha1A subunit of the Cav2.1 channels, which conduct P/Q-type Ca2+ currents, has been confirmed in in vitro-translated proteins and brain membrane studies, the question of how native proteins can establish this association in situ in developing neurons remains to be elucidated. Here we report data regarding this interaction in bovine chromaffin cells natively expressing both proteins. The two carboxyl-terminal splice variants of the alpha1A subunit identified in these cells share a synaptic protein interaction ('synprint') site within the II/III loop segment and are immunodetected by a specific antibody against bovine alpha1A protein. Moreover, both alpha1A isoforms form part of the P/Q-channels-SNARE complexes in situ because they are coimmunoprecipitated from solubilized chromaffin cell membranes by a monoclonal SNAP-25 antibody. The distribution of alpha1A and SNAP-25 was studied in round or transdifferentiated chromaffin cells using confocal microscopy and specific antibodies: the two proteins are colocalized at the cell body membrane in both natural cell types. However, during the first stages of the cell transdifferentiation process, SNAP-25 migrates alone out to the developing growth cone and what will become the nerve endings and varicosities of the mature neurites; alpha1A follows and colocalizes to SNAP-25 in the now mature processes. These observations lead us to propose that the association between SNAP-25 and alpha1A during neuritogenesis might promote not only the efficient coupling of the exocytotic machinery but also the correct insertion of P/Q-type channels at specialized active zones in presynaptic neuronal terminals.


Assuntos
Canais de Cálcio Tipo N/metabolismo , Células Cromafins/citologia , Células Cromafins/fisiologia , Neuritos/metabolismo , Subunidades Proteicas/metabolismo , Proteína 25 Associada a Sinaptossoma/metabolismo , Animais , Sequência de Bases , Northern Blotting/métodos , Western Blotting/métodos , Cálcio/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio Tipo N/genética , Bovinos , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/fisiologia , Células Cultivadas , Células Cromafins/classificação , Células Cromafins/efeitos dos fármacos , Dopamina beta-Hidroxilase/metabolismo , Relação Dose-Resposta a Droga , Imunofluorescência/métodos , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Imunoprecipitação/métodos , Camundongos , Microscopia Confocal/métodos , Modelos Moleculares , Fosfatidiletanolamina N-Metiltransferase/metabolismo , Potássio/farmacologia , Subunidades Proteicas/genética , RNA Mensageiro/metabolismo , Coelhos , Ratos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Alinhamento de Sequência/métodos , Proteína 25 Associada a Sinaptossoma/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA